Therapie des Ovarialkarzinoms im Wandel

Das Ovarialkarzinom ist nach wie vor schwer zu therapieren – auch nach optimaler operativer und medikamentöser Therapie kommt es häufig zum Rezidiv. Aktuelle Studien mit PARP-Inhibitoren als Monotherapie oder in Kombinationen machen Hoffnung auf eine baldige Ablösung des alten Goldstandards Chemotherapie.

Publication History

Article published online:
28 January 2021

• Literatur

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
• 2 International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. In: Online Analysis 9 Prediction. Lyon, France: IARC (International Agency for Research on Cancer); 2016
• 3 Jacobs IJ, Menon U, Ryan A. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening. (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 945-956
• 4 Leitlinienprogramm Onkologie (DGK, DGGG, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 4.0, April 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/
• 5 Leitzmann MF, Koebnick C, Danforth KN. et al. Body mass index and risk of ovarian cancer. Cancer 2009; 115: 812-822
• 6 Cannioto R, LaMonte MJ. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2016; 25: 1114-1124
• 7 Jaeger A, Wölber L, Prieske K. et al. Genetik und Prävention des Ovarialkarzinoms. TumorDiagn Therap 2018; 39: 165-170
• 8 Beral V, Gaitskell K, Hermon C. et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710
• 9 Kurman RJ, Carcangiu ML, Herrington CS. et al. WHO Classification of Tumors of Female Reproductive Organs. Lyon: IARC; 2014
• 10 Robert-Koch-Institut. Bericht zum Krebsgeschehen in Deutschland. 2016
• 11 Shih-le M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518
• 12 Kobel M, Rahimi K, Rambau PF. et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. Int J Gynecol Pathol 2016; 35: 430-441
• 13 Staebler A. Pathologische Diagnostik der Ovarialkarzinome. TumorDiagn Therap 2018; 39: 171-176
• 14 Buderath P, Kimmig R. Ovarialkarzinom – Diagnostik und Therapie. Onkologe 2020; 26: 569-576
• 15 Trimbos B, Timmers P, Pecorelli S. et al. Surgical stagingand treatmentof early ovarian cancer: long-term analysis from a randomized trial. JNCIJ Natl Cancer Inst J 2010; 102: 982-987
• 16 Du Bois A, Reuss A, Pujade-lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'lnvestigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115: 1234-1244
• 17 Harter P, Sehouli J, Lorusso D. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019; 380: 822-832
• 18 du Bois A, Vergote I, Ferron G. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. ASCO 2017. J Clin Oncol 2017; 35: Abstr. 5501
• 19 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257
• 20 de Gregorio N. Meilensteine in der Therapie des Ovarialkarzinoms. TumorDiagn Therap 2018; 39: 177-179
• 21 Zumdick C. Ovarialkarzinom – Aktuelle PARP-Inhibitoren im Fokus. Privatarzt Gynäkol 2020; 11 (06) 12-14
• 22 Moore K, Colombo N, Scambia G. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018; 379: 2495-2505
• 23 Coleman RL, Oza AM, Lorusso D. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 1949-1961
• 24 González-Martín A, Pothuri B, Vergote I. et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019; 381: 2391-2402
• 25 Ray-Coquard I, Pautier P, Pignata S. et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 2019; 381: 2416-2428
• 26 Mirza MR, Coleman RL, González-Martín A. et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol 2020; 31: 1948-1959